Treatment of patients with nonsevere and severe coronavirus disease 2019: An evidencebased guideline

CMAJ

Volumn 192, Issue 20, 2020, Pages 536-545

  Ye, Zhikang ^a   Rochwerg, Bram ^a   Wang, Ying ^b   Adhikari, Neill K ^c,d   Murthy, Srinivas ^e   Lamontagne, Francois ^f,g   Fowler, Robert A ^c,d   Qiu, Haibo ^h   Wei, Li ⁱ   Sang, Ling ^j   Loeb, Mark ^a   Shen, Ning ^k   Huang, Minhua ^l   Jiang, Zhaonan ^m   Arabi, Yaseen M ⁿ   Colunga Lozano, Luis Enrique ^a,o   Jiang, Li ^p   Koh, Younsuck ^q   Liu, Dong ^r   Liu, Fang ^k   Phua, Jason ^s   Shen, Aizong ^t   Huo, Tianyi ^k   Du, Bin ^u   Zhai, Suodi ^k   Guyatt, Gordon H ^a   more..

^a MCMASTER UNIVERSITY   (Canada)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TORONTO   (Canada)

^d Canada   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITÉ DE SHERBROOKE   (Canada)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^h MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

ⁱ GUANGZHOU UNIVERSITY   (China)

^j GUANGZHOU MEDICAL UNIVERSITY   (China)

^k PEKING UNIVERSITY   (China)

^l Guangdong Kuaiwen Information Technology Co LTD   (China)

^m Kunshan Guanghui Precise Metal Co Ltd   (China)

ⁿ KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^o UNIVERSITY OF GUADALAJARA   (Mexico)

^p CAPITAL MEDICAL UNIVERSITY   (China)

^q University of Ulsan College of Medicine   (South Korea)

^r HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^s NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^t UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^u PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FAVIPIRAVIR; HYDROXYCHLOROQUINE; LOPINAVIR; RIBAVIRIN; RITONAVIR; UMIFENOVIR; ANTIVIRUS AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CORONAVIRUS DISEASE 2019; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; HEALTH CARE PLANNING; HUMAN; NONHUMAN; PATIENT CARE; PLASMA; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; CORONAVIRUS INFECTION; EVIDENCE BASED MEDICINE; PANDEMIC; SEVERITY OF ILLNESS INDEX; VIRUS PNEUMONIA;

ADRENAL CORTEX HORMONES; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; EVIDENCE-BASED MEDICINE; HUMANS; PANDEMICS; PLASMA; PNEUMONIA, VIRAL; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 85084616530     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.200648     Document Type: Article

References (55)

1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020 Feb. 28 [Epub ahead of print]. doi: 10.1056/NEJMoa2002032.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497-506.
3. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020 Mar. 13 [Epub ahead of print]. doi: 10.1001/jamainternmed.2020.0994.
4. Coehn E, Bonifield J, Nigam M. Trump says this drug has "tremendous promise, " but Fauci's not spending money on it. CNN 2020 Apr. 10. Available: www. cnn.com/2020/03/28/health/coronavirus-hydroxychloroquine-trial/index.html (accessed 2020 Apr. 26).
5. Kalil AC. Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA 2020 Mar. 24 [Epub ahead of print]. doi: 10.1001/jama.2020.4742.
6. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines; Graham R, Mancher M, Miller Wolman D, et al, editors. Clinical practice guidelines we can trust. Washington (D.C.): National Academy of Sciences; 2011.
7. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6.
8. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance. Geneva: World Health Organization; 2020 Mar. 13.
9. Ye Z, Wang Y, Colunga-Lozano L, et al. Efficacy and safety of corticosteroids in COVID-19: A systematic review and meta-analysis including summaries of indirect evidence from ARDS, SARS, MERS, influenza, and community acquired pneumonia. CMAJ 2020. In press.
10. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020 Apr. 12 [Epub ahead of print]. doi: 10.1016/j.jaci.2020.04.006.
11. Lu X, Chen T, Wang Y, et al. Adjuvant corticosteroid therapy for critically ill patients with COVID-19. MedRxiv 2020 Apr. 7. doi: 10.1101/2020.04.07.20056390.
12. Lau EHY, Cowling BJ, Muller MP, et al. Effectiveness of ribavirin and corticosteroids for severe acute respiratory syndrome. Am J Med 2009; 122:1150.e11-21.
13. Long Y, Xu Y, Wang B, et al. Clinical recommendations from an observational study on MERS: Glucocorticoids was benefit in treating SARS patients. Int J Clin Exp Med 2016; 9:8865-73.
14. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 2018; 197:757-67.
15. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10:676-8.
16. Devasenapathy N, Ye Z, Loeb M, et al. Indirect evidence on efficacy and safety of convalescent plasma in severe COVID-19 patients: Systematic review and meta-analysis. CMAJ 2020. In press.
17. Beigel JH, Aga E, Elie-Turenne MC, et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: A randomised, double-blind, phase 3 trial. Lancet Respir Med 2019; 7:941-50.
18. Beigel JH, Tebas P, Elie-Turenne MC, et al. Immune plasma for the treatment of severe influenza: An open-label, multicentre, phase 2 randomised study. Lancet Respir Med 2017; 5:500-11.
19. Davey RT, Fernandez-Cruz E, Markowitz N, et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): A double-blind, randomised, placebo-controlled trial. Lancet Respir Med 2019; 7:951-63.
20. Hung IFN, To KKW, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013; 144:464-73.
21. Li Y, Xie Z, Lin W, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). medRxiv 2020 Apr. 15. doi: 10.110/2020.03.19.2 0038984.
22. Liu W, Zhou P, Chen K, et al. Efficacy and safety of antiviral agents in COVID-19 patients: Systematic review and meta-analysis. CMAJ 2020. In press.
23. Yan D, Liu X-y, Zhu Y-n, et al. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection. medRxiv 2020 Mar. 30. doi: 10.1101/2020.03.22.20040832.
24. Zhou Q, Wei X-S, Xiang X, et al. Interferon-a2b treatment for COVID-19. medRxiv 2020 Apr. 10. doi: 10.1101/2020.04.06.20042580.
25. Chen C, Huang J, Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: A randomized clinical trial. medRxiv 2020 Apr. 15. doi: 10.1101/2020.03.17.20037432.
26. Cai QX, Yang MH, Liu DJ, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering 2020 Mar. 18 doi: 10.1016/j. eng.2020.03.007.
27. Muller MP, Dresser L, Raboud J, et al. Adverse events associated with highdose ribavirin: Evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy 2007; 27:494-503.
28. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020 Mar. 18. doi: 10.1056/NEJMoa2001282. [Epub ahead of print].
29. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci) 2020 Mar. 6. doi: 10.3785/j.issn.1008-9292.2020.03.03.
30. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial. medRxiv 2020 Apr. 10. doi: 10.1101/2020.03.22.20040758.
31. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: An open-label, randomized, controlled trial. medRxiv 2020 Apr. 14 doi: 10.1101/20 20.04.10.20060558.
32. Al Ghamdi M, Alghamdi KM, Ghandoora Y, et al. Treatment outcomes for patients with Middle Eastern respiratory syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect Dis 2016; 16:174.
33. Leong HN, Ang B, Earnest A, et al. Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003. Trop Med Int Health 2004; 9:923-7.
34. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: A retrospective study. J Antimicrob Chemother 2015; 70:2129-32.
35. Liu Q, Fang X, Tian L, et al. The effect of arbidol hydrochloride on reducing mortality of COVID-19 patients: A retrospective study of real-world date from three hospitals in Wuhan. medRxiv 2020 Apr. 17. doi: 10.1101/2020.04.11.20056523.
36. Dose-finding study of favipiravir in the treatment of uncomplicated influenza. ClinicalTrials.gov: NCT01068912; 2010. Available: www.clinicaltrials.gov/show/NCT01068912 (accessed 2020 Mar. 28).
37. Mahevas M, Tran VT, Roumier M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: Results of a study using routinely collected data to emulate a target trial. medRxiv 2020 Apr. 14. doi: 10.1101/2020.04.10.20060699.
38. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv 2020 Apr. 23. doi: 10.1101/2020.04.16.20065920.
39. Higgins JPT, Thomas J, editors. Cochrane handbook for systematic reviews of interventions version 6.0. Oxford (UK): The Cochrane Collaboration; updated July 2019.
40. Guyatt GH, Busse JW. Modification of Cochrane tool to assess risk of bias in randomized trials. Ottawa: Evidence Partners. Available: www.evidencepartners. com/resources/methodological-resources/(accessed 2020 Apr. 26).
41. Busse JW, Guyatt GH. Tool to assess risk of bias in cohort studies. Ottawa: Evidence Partners. Available: www.evidencepartners.com/resources/methodological -resources/(accessed 2020 Apr. 26).
42. Busse JW, Guyatt GH. Tool to assess risk of bias in case-control studies. Ottawa: Evidence Partners. Available: www.evidencepartners.com/resources/methodological-resources/(accessed 2020 Apr. 26).
43. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64:401-6.
44. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. rating the quality of evidence - study limitations (risk of bias). J Clin Epidemiol 2011; 64:407-15.
45. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. rating the quality of evidence - imprecision. J Clin Epidemiol 2011; 64:1283-93.
46. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. rating the quality of evidence - inconsistency. J Clin Epidemiol 2011; 64:1294-302.
47. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. rating the quality of evidence - indirectness. J Clin Epidemiol 2011; 64:1303-10.
48. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. rating the quality of evidence - publication bias. J Clin Epidemiol 2011; 64:1277-82.
49. Guyatt GH, Oxman AD, Sultan S, et al. GRADE guidelines: 9. rating up the quality of evidence. J Clin Epidemiol 2011; 64:1311-6.
50. Schunemann HJ, Al-Ansary LA, Forland F, et al. Guidelines International Network: Principles for disclosure of interests and management of conflicts in guidelines. Ann Intern Med 2015; 163:548-53.
51. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Arlington (VA): Infectious Disease Society of America; 2020. Available: www. idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/(accessed 2020 Apr. 26).
52. Alhazzani W, Moller MH, Arabi YM, et al. Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med 2020 Mar. 28 [Epub ahead of print]. doi: 10.1007/s00134-020-06022-5.
53. COVID-19 guidelines version 1. Camberwell (AU): The Australian and New Zealand Intensive Care Society (ANZICS); 2020. Available: www.anzics.com.au/coronavirus-guidelines/(accessed 2020 Apr. 26).
54. COVID-19 rapid guideline: Managing suspected or confirmed pneumonia in adults in the community. London (UK): National Institute for Health and Care Excellence; 2020. Available: www.nice.org.uk/guidance/ng165 (accessed 2020 Apr. 26).
55. Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients. ISRCTN Registry. ISRCTN83971151; 2020. Available: www.isrctn.com/ISRCTN83971151 (accessed 2020 Apr. 26).